Search Results - "CROFT, Simon L"

Drug Resistance in Leishmaniasis by CROFT, Simon L, SUNDAR, Shyam, FAIRLAMB, Alan H

“…Classifications Services CMR Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Activity of Amphotericin B-Loaded Chitosan Nanoparticles against Experimental Cutaneous Leishmaniasis by Riezk, Alaa, Van Bocxlaer, Katrien, Yardley, Vanessa, Murdan, Sudaxshina, Croft, Simon L

“…Chitosan nanoparticles have gained attention as drug delivery systems (DDS) in the medical field as they are both biodegradable and biocompatible with reported…”
Get full text

A potent series targeting the malarial cGMP-dependent protein kinase clears infection and blocks transmission by Baker, David A., Stewart, Lindsay B., Large, Jonathan M., Bowyer, Paul W., Ansell, Keith H., Jiménez-Díaz, María B., El Bakkouri, Majida, Birchall, Kristian, Dechering, Koen J., Bouloc, Nathalie S., Coombs, Peter J., Whalley, David, Harding, Denise J., Smiljanic-Hurley, Ela, Wheldon, Mary C., Walker, Eloise M., Dessens, Johannes T., Lafuente, María José, Sanz, Laura M., Gamo, Francisco-Javier, Ferrer, Santiago B., Hui, Raymond, Bousema, Teun, Angulo-Barturén, Iñigo, Merritt, Andy T., Croft, Simon L., Gutteridge, Winston E., Kettleborough, Catherine A., Osborne, Simon A.

“…To combat drug resistance, new chemical entities are urgently required for use in next generation anti-malarial combinations. We report here the results of a…”
Get full text

Leishmaniasis by Burza, Sakib, Croft, Simon L, Boelaert, Marleen

“…Leishmaniasis is a poverty-related disease with two main clinical forms: visceral leishmaniasis and cutaneous leishmaniasis. An estimated 0·7–1 million new…”
Get full text

Chitosan Contribution to Therapeutic and Vaccinal Approaches for the Control of Leishmaniasis by Loiseau, Philippe M, Pomel, Sébastien, Croft, Simon L

“…The control of leishmaniases, a complex parasitic disease caused by the protozoan parasite , requires continuous innovation at the therapeutic and vaccination…”
Get full text

Innovations for the elimination and control of visceral leishmaniasis by Selvapandiyan, Angamuthu, Croft, Simon L, Rijal, Suman, Nakhasi, Hira L, Ganguly, Nirmal K

“…Discussions and debates throughout the conference were aimed to provide a focus for stakeholders and decision makers to frame further control measures and…”
Get full text

Topical formulations of miltefosine for cutaneous leishmaniasis in a BALB/c mouse model by Van Bocxlaer, Katrien, Yardley, Vanessa, Murdan, Sudaxshina, Croft, Simon L.

“…Cutaneous leishmaniasis (CL) is caused by several species of the protozoan parasite Leishmania and affects approximately 10 million people worldwide. Currently…”
Get full text

Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis by Caridha, Diana, Vesely, Brian, van Bocxlaer, Katrien, Arana, Byron, Mowbray, Charles E., Rafati, Sima, Uliana, Silvia, Reguera, Rosa, Kreishman-Deitrick, Mara, Sciotti, Richard, Buffet, Pierre, Croft, Simon L.

“…Although there have been significant advances in the treatment of visceral leishmaniasis (VL) and several novel compounds are currently in pre-clinical and…”
Get full text

In Vitro and In Vivo Interactions between Miltefosine and Other Antileishmanial Drugs by SEIFERT, Karin, CROFT, Simon L

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Development of an in vitro media perfusion model of Leishmania major macrophage infection by O'Keeffe, Alec, Hyndman, Lauren, McGinty, Sean, Riezk, Alaa, Murdan, Sudaxshina, Croft, Simon L

“…In vitro assays are widely used in studies on pathogen infectivity, immune responses, drug and vaccine discovery. However, most in vitro assays display…”
Get full text

Leishmaniasis– current chemotherapy and recent advances in the search for novel drugs by Croft, Simon L., Coombs, Graham H.

“…The chemotherapy currently available for leishmaniasis is far from satisfactory. Resistance to the pentavalent antimonials, which have been the recommended…”
Get full text

Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis by Van Bocxlaer, Katrien, Caridha, Diana, Black, Chad, Vesely, Brian, Leed, Susan, Sciotti, Richard J., Wijnant, Gert-Jan, Yardley, Vanessa, Braillard, Stéphanie, Mowbray, Charles E., Ioset, Jean-Robert, Croft, Simon L.

“…Drugs for Neglected Diseases initiative (DNDi) has identified three chemical lead series, the nitroimidazoles, benzoxaboroles and aminopyrazoles, as innovative…”
Get full text

Costs and outcomes of active and passive case detection for visceral leishmaniasis (Kala-Azar) to inform elimination strategies in Bihar, India by Dial, Natalie J, Medley, Graham F, Croft, Simon L, Mahapatra, Tanmay, Priyamvada, Khushbu, Sinha, Bikas, Palmer, Lucy, Terris-Prestholt, Fern

“…Effective case identification strategies are fundamental to capturing the remaining visceral leishmaniasis (VL) cases in India. To inform government strategies…”
Get full text

Review of pyronaridine anti-malarial properties and product characteristics by Croft, Simon L, Duparc, Stephan, Arbe-Barnes, Sarah J, Craft, J Carl, Shin, Chang-Sik, Fleckenstein, Lawrence, Borghini-Fuhrer, Isabelle, Rim, Han-Jong

“…Pyronaridine was synthesized in 1970 at the Institute of Chinese Parasitic Disease and has been used in China for over 30 years for the treatment of malaria…”
Get full text

Antileishmanial and Antitrypanosomal Activities of the 8-Aminoquinoline Tafenoquine by YARDLEY, Vanessa, GAMARRO, Francisco, CROFT, Simon L

“…ERRATUM ( vol. 55 , p. 458 ) Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg…”
Get full text

Highly sensitive in vivo imaging of Trypanosoma brucei expressing "red-shifted" luciferase by McLatchie, Alex P, Burrell-Saward, Hollie, Myburgh, Elmarie, Lewis, Michael D, Ward, Theresa H, Mottram, Jeremy C, Croft, Simon L, Kelly, John M, Taylor, Martin C

“…Human African trypanosomiasis is caused by infection with parasites of the Trypanosoma brucei species complex, and threatens over 70 million people in…”
Get full text

Drug reformulation for a neglected disease. The NANOHAT project to develop a safer more effective sleeping sickness drug by Sanderson, Lisa, da Silva, Marcelo, Sekhar, Gayathri N, Brown, Rachel C, Burrell-Saward, Hollie, Fidanboylu, Mehmet, Liu, Bo, Dailey, Lea Ann, Dreiss, Cécile A, Lorenz, Chris, Christie, Mark, Persaud, Shanta J, Yardley, Vanessa, Croft, Simon L, Valero, Margarita, Thomas, Sarah A

“…Human African trypanosomiasis (HAT or sleeping sickness) is caused by the parasite Trypanosoma brucei sspp. The disease has two stages, a haemolymphatic stage…”
Get full text

Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome® and AmBisome® in murine cutaneous leishmaniasis by Wijnant, Gert-Jan, Van Bocxlaer, Katrien, Yardley, Vanessa, Harris, Andy, Alavijeh, Mo, Silva-Pedrosa, Rita, Antunes, Sandra, Mauricio, Isabel, Murdan, Sudaxshina, Croft, Simon L.

“…Fungisome® (F), a liposomal amphotericin B (AmB) product, is marketed in India as a safe and effective therapeutic for the parasitic infection visceral…”
Get full text

Pharmacokinetic / pharmacodynamic relationships of liposomal amphotericin B and miltefosine in experimental visceral leishmaniasis by Voak, Andrew A, Harris, Andy, Coteron-Lopez, Jose Miguel, Angulo-Barturen, Iñigo, Ferrer-Bazaga, Santiago, Croft, Simon L, Seifert, Karin

“…There is a continued need to develop effective and safe treatments for visceral leishmaniasis (VL). Preclinical studies on pharmacokinetics and…”
Get full text

Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda by Guerin, Philippe J, Olliaro, Piero, Sundar, Shyam, Boelaert, Marleen, Croft, Simon L, Desjeux, Philippe, Wasunna, Monique K, Bryceson, Anthony D M

“…Visceral leishmaniasis is common in less developed countries, with an estimated 500000 new cases each year. Because of the diversity of epidemiological…”
Get more information